Report: Tracking system needed to fight fake drugs

by Lauran Neergaard

(AP)—A new report calls for a national drug tracking system to fight the growing problem of fake drugs.

The Institute of Medicine says phony or substandard drugs are an increasing international threat, and one that is affecting the U.S. as well.

Just last week, the warned doctors—for the third time in about a year—that it discovered a counterfeit batch of the cancer drug Avastin, one that lacks the real tumor-killing ingredient.

Wednesday's report says mandatory drug tracking would offer the same kind of reliability for medications that the U.S. court system's chain-of-custody requirements do for evidence used in trials. It would allow verification that a drug and the ingredients used to make it are authentic at every step.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

US warns of new fake batch of cancer drug Avastin

Feb 06, 2013

The Food and Drug Administration is warning U.S. doctors about another counterfeit version of the cancer drug Avastin, the third case involving the best-selling Roche drug in the past year.

Fake Avastin contained several chemicals, no drug

Feb 28, 2012

(AP) -- Counterfeit versions of the popular cancer drug Avastin obtained by European regulators contain a variety of chemicals, but not the active ingredient found in the genuine drug, according to drugmaker Roche.

FDA finds more vials of fake cancer drug

Apr 04, 2012

(AP) -- The Food and Drug Administration is warning doctors that a second counterfeit version of the best-selling cancer drug Avastin has been found in the U.S., packaged as the Turkish brand of the medication.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments